Cellectis’ 'off the shelf' CAR-T cancer therapy has hit a major setback after the first patient treated in a phase 1 study died, and the first patient treated in another developed life-thr
Trials of Cellectis’ UCART123 have been given the go-ahead by the FDA, which will make it the first ‘off the shelf’ CAR-T drug to enter trials in the US.